Advertisement

Prognostic importance of the preoperative modified systemic inflammation score for patients with gastric cancer

  • Jian-Xian Lin
  • Jun-Peng Lin
  • Jian-Wei Xie
  • Jia-bin Wang
  • Jun Lu
  • Qi-Yue Chen
  • Long-long Cao
  • Mi Lin
  • Ruhong Tu
  • Chao-Hui Zheng
  • Chang-Ming Huang
  • Ping Li
Original Article

Abstract

Background

The systemic inflammation score (SIS), based on preoperative serum albumin (Alb) level and lymphocyte-to-monocyte ratio (LMR), has been shown to be a novel prognostic score for some tumors. We investigate the prognostic value of the SIS in patients with resectable gastric cancer (GC).

Methods

Patients with GC who underwent curative resection between December 2008 and December 2013 were included. Time-dependent receiver operating characteristics analysis (t-ROC), concordance index (C-index) and AUC were used to compare the prognostic impact.

Results

Totally, 1786 patients with resectable GC were included in the study. By multivariate analysis, the SIS was not an independent prognostic factor. However, the normal Alb level (≥ 40 g/l) and LMR ≥ 3.4 both remained independent protective factors for GC (both P < 0.05). Due to the similar survival of patients with LMR ≥ 3.4 and LMR < 3.4 in the normal Alb group, we combined the two subgroups to establish the modified SIS (mSIS). Multivariate analysis revealed that the mSIS was the only significant independent biomarker (P < 0.05). The t-ROC curve and C-index for the mSIS were superior to those of the SIS throughout the observation period. Furthermore, the AUC of the mSIS was significantly greater than that of the SIS at 3 and 5 years after operation (both P < 0.05).

Conclusion

The preoperative mSIS is a novel, simple and useful prognostic factor for postoperative survival in patients with GC and can be used as a part of the preoperative risk stratification process to improve the prediction of clinical outcomes.

Keywords

Gastric cancer Systemic inflammation score Lymphocyte-to-monocyte ratio Albumin Prognosis 

Notes

Acknowledgements

Scientific and technological innovation joint capital projects of Fujian Province, China (no. 2016Y9031). Minimally invasive medical center of Fujian Province (no. [2017]171). Project supported by the Science Foundation of the Fujian Province, China (Grant no. 2018J01307). Startup Fund for scientific research, Fujian Medical University (no. 2016QH024).

Author contributions

LJX, LJP, ZCH, HCM and LP conceived of the study, analyzed the data, and drafted the manuscript; TRH, LP, XJW, WJB, and LP helped revise the manuscript critically for important intellectual content; LJ, CQY, CLL, and LM helped collect data and design the study.

Compliance with ethical standards

Conflict of interest

There are no conflicts of interest or financial ties to disclose from any of author.

Human rights statement

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.

Informed consent

Informed consent or substitute for it was obtained from all patients for being included in the study.

Supplementary material

10120_2018_854_MOESM1_ESM.tif (199 kb)
Supplementary material 1 (TIF 199 KB)
10120_2018_854_MOESM2_ESM.tif (77 kb)
Supplementary material 2 (TIF 76 KB)
10120_2018_854_MOESM3_ESM.tif (53 kb)
Supplementary material 3 (TIF 52 KB)
10120_2018_854_MOESM4_ESM.tif (33 kb)
Supplementary material 4 (TIF 33 KB)
10120_2018_854_MOESM5_ESM.doc (53 kb)
Supplementary material 5 (DOC 53 KB)
10120_2018_854_MOESM6_ESM.doc (28 kb)
Supplementary material 6 (DOC 28 KB)
10120_2018_854_MOESM7_ESM.doc (64 kb)
Supplementary material 7 (DOC 64 KB)

References

  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefGoogle Scholar
  2. 2.
    Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–45.CrossRefPubMedGoogle Scholar
  3. 3.
    McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–40.CrossRefPubMedGoogle Scholar
  4. 4.
    Lin JP, Lin JX, Cao LL, et al. Preoperative lymphocyte-to-monocyte ratio as a strong predictor of survival and recurrence for gastric cancer after radical-intent surgery. Oncotarget. 2017;8(45):79234–47.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Kim EY, Lee JW, Yoo HM, et al. The platelet-to-lymphocyte ratio versus neutrophil-to-lymphocyte ratio: which is better as a prognostic factor in gastric cancer? Ann Surg Oncol. 2015;22(13):4363–70.CrossRefPubMedGoogle Scholar
  6. 6.
    Suzuki Y, Okabayashi K, Hasegawa H, et al. Comparison of preoperative inflammation-based prognostic scores in patients with colorectal cancer. Ann Surg. 2018;267(3):527–31.PubMedCrossRefGoogle Scholar
  7. 7.
    Chang Y, An H, Xu L, et al. Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma. Br J Cancer. 2015;113(4):626–33.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;2:113–23.Google Scholar
  9. 9.
    Edge SB, Byrd D. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.Google Scholar
  10. 10.
    Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21.CrossRefPubMedGoogle Scholar
  11. 11.
    Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387–93.CrossRefPubMedGoogle Scholar
  12. 12.
    D’Angelica M, Gonen M, Brennan MF, et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240(5):808–16.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337–44.CrossRefPubMedGoogle Scholar
  15. 15.
    Rodriguez-Alvarez MX, Meira-Machado L, Abu-Assi E, Raposeiras-Roubin S. Nonparametric estimation of time-dependent ROC curves conditional on a continuous covariate. Stat Med. 2016;35(7):1090–102.CrossRefPubMedGoogle Scholar
  16. 16.
    Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.CrossRefPubMedGoogle Scholar
  17. 17.
    Gu L, Li H, Chen L, et al. Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis. Oncotarget. 2016;7(22):31926–42.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Koh YW, Park CS, Yoon DH, et al. Should the cut-off values of the lymphocyte to monocyte ratio for prediction of prognosis in diffuse large B-cell lymphoma be changed in elderly patients? Eur J Haematol. 2014;93(4):340–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Zheng G, Feng F, Guo M, et al. Harvest of at least 23 lymph nodes is indispensable for stage N3 gastric cancer patients. Ann Surg Oncol. 2017;24(4):998–1002.CrossRefPubMedGoogle Scholar
  20. 20.
    Qureshi YA, Sarker SJ, Walker RC, Hughes SF. Proximal resection margin in Ivor–Lewis oesophagectomy for cancer. Ann Surg Oncol. 2017;24(2):569–77.CrossRefPubMedGoogle Scholar
  21. 21.
    Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;2:137–48.CrossRefGoogle Scholar
  22. 22.
    Azimi F, Scolyer RA, Rumcheva P, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012;21:2678–83.CrossRefGoogle Scholar
  23. 23.
    Augier S, Ciucci T, Luci C, Carle GF, Blin-Wakkach C, Wakkach A. Inflammatory blood monocytes contribute to tumor development and represent a privileged target to improve host immunosurveillance. J Immunol. 2010;12:7165–73.CrossRefGoogle Scholar
  24. 24.
    Evani SJ, Prabhu RG, Gnanaruban V, Finol EA, Ramasubramanian AK. Monocytes mediate metastatic breast tumor cell adhesion to endothelium under flow. FASEB J. 2013;8:3017–29.CrossRefGoogle Scholar
  25. 25.
    Crumley AB, Stuart RC, McKernan M, McMillan DC. Is hypoalbuminemia an independent prognostic factor in patients with gastric cancer? World J Surg. 2010;34(10):2393–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Lien YC, Hsieh CC, Wu YC, et al. Preoperative serum albumin level is a prognostic indicator for adenocarcinoma of the gastric cardia. J Gastrointest Surg. 2004;8(8):1041–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Forrest LM, McMillan DC, McArdle CS, et al. A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2005;92(10):1834–6.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Al MA, Bartlett JM, Canney PA, et al. Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer. 2006;94(2):227–30.CrossRefGoogle Scholar
  29. 29.
    Crumley AB, McMillan DC, McKernan M, et al. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer. 2006;94(5):637–41.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Glen P, Jamieson NB, McMillan DC, et al. Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology. 2006;6(5):450–3.CrossRefPubMedGoogle Scholar
  31. 31.
    Melling N, Gruning A, Tachezy M, et al. Glasgow Prognostic Score may be a prognostic index for overall and perioperative survival in gastric cancer without perioperative treatment. Surgery. 2016;159(6):1548–56.CrossRefPubMedGoogle Scholar
  32. 32.
    Sato B, Kanda M, Tanaka C, et al. Significance of preoperative systemic inflammation score in short-term and long-term outcomes of patients with pathological T2–4 gastric cancer after radical gastrectomy. World J Surg. 2018.  https://doi.org/10.1007/s00268-018-4597-7.PubMedCrossRefGoogle Scholar

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2018

Authors and Affiliations

  • Jian-Xian Lin
    • 1
    • 2
    • 3
  • Jun-Peng Lin
    • 1
    • 2
  • Jian-Wei Xie
    • 1
    • 2
    • 3
  • Jia-bin Wang
    • 1
    • 2
    • 3
  • Jun Lu
    • 1
    • 2
  • Qi-Yue Chen
    • 1
    • 2
  • Long-long Cao
    • 1
    • 2
  • Mi Lin
    • 1
    • 2
  • Ruhong Tu
    • 1
    • 2
  • Chao-Hui Zheng
    • 1
    • 2
    • 3
  • Chang-Ming Huang
    • 1
    • 2
    • 3
  • Ping Li
    • 1
    • 2
    • 3
  1. 1.Department of Gastric SurgeryFujian Medical University Union HospitalFuzhouChina
  2. 2.Department of General SurgeryFujian Medical University Union HospitalFuzhouChina
  3. 3.Key Laboratory of Ministry of Education of Gastrointestinal CancerFujian Medical UniversityFuzhouChina

Personalised recommendations